Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... About us

We are an independent, family-owned company with headquarters in Aachen, Germany. We are present in 29 countries with affiliates in Europe, Latin America and the USA. Our products are sold in more than 155 countries and we employ around 4,700 employees worldwide.

... Company Overview

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

At Grünenthal, conducting our business responsibly is a core part of our company’s strategy and culture. As a global leader in pain management, Grünenthal aspires to create a positive impact on society – in our core business and beyond. We are guided by integrity, transparency and the highest ethical standards.

... Responsibility

Patients’ needs are at the heart of everything we do; using our passion for science, we develop long-lasting solutions that directly address these needs.

... Products

We are dedicated to creating a better future for our patients, so getting involved with diverse initiatives that support this goal is vital.

... Initiatives

... Requests for funding

Where we come from

Although firmly rooted in Germany, today we are very much a growing global business. An integrated research and development company, we have an enviable track record of bringing effective pain treatments and state-of-the-art technologies to patients. Our high level of investment in R&D is testament to our unwavering commitment to innovation.

Grünenthal Pharma Ltd., Ireland, a wholly owned subsidiary of Grünenthal GmbH, was established in 2005. With headquarters in Dublin, the company distributes and markets pain and anti-infective products under an exclusive distribution agreement with Grünenthal GmbH.

Grünenthal Pharma Limited markets: Palexia Film Coated Tablets®, Palexia SR®, Qutenza®, Vimovo®, Nexium®, Versatis®, Zomig, Ixprim®, Ixprim Effervescent®, Zydol® (tramadol HCI) and Zydol SR®.

Thalidomide

Thalidomide will always be a significant part of our company history.

Visit website

Where we come from

2005 Company Launch

2008 Ixprim®

2011 Versatis®

2011 Palexia®

2018 Qutenza

Thalidomide